Drug intelligence / Profile preview

ocaratuzumab

Development stage: Phase 1
Lead developer: Mentrik Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Ocaratuzumab is a humanized Fc-engineered IgG1 monoclonal antibody targeting the CD20 antigen on B lymphocytes. It is designed for enhanced affinity to CD20 and increased antibody-dependent cell-mediated cytotoxicity (ADCC), particularly in patients with low-affinity FcγRIIIa allotypes. Ocaratuzumab demonstrates greater ADCC potency at lower concentrations compared to rituximab and similar activity to obinutuzumab. Its improved efficacy may allow for subcutaneous administration and lower dosing requirements. Ocaratuzumab has been investigated in phase I/II trials for relapsed/refractory follicular lymphoma and rheumatoid arthritis, with ongoing development in other oncology and rheumatology indications[1][2][3][4][5][7].

Other names: ocaratuzumabAME-133vAME133vAME 133vLY2469298LY-2469298LY 2469298

Targets

FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on ocaratuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ocaratuzumab.

Explore the full profile